Venous Thromboembolism Risk Associated with Relugolix-Estradiol-Norethisterone Acetate Combination Therapy Article Swipe
Marie Didembourg
,
Charles Chapron
,
Philippe Descamps
,
Florence Trémollières
,
Nathalie Chabbert‐Buffet
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1210/jendso/bvaf190
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1210/jendso/bvaf190
Background Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol (E2) and norethisterone acetate (NETA). Objective This expert opinion evaluates the thrombotic risk of relugolix-CT based on pharmacological data, clinical trials, and regulatory assessments. Methods A review of pivotal trials (LIBERTY 1, LIBERTY 2, SPIRIT 1, SPIRIT 2), regulatory reports (EMA, FDA), and real-world safety data was conducted, focusing on hemostatic effects and VTE risk. Results Relugolix monotherapy reduces estrogen levels, leading to minor decreases in coagulation factors. While E2 and NETA mitigate hypoestrogenic effects, concerns about their prothrombotic potential remain. However, clinical trials and post-marketing surveillance have not shown a significant increase in VTE risk. A meta-analysis suggests that estradiol-based regimens have a lower thrombotic risk than ethinylestradiol-based therapies. Conclusions The VTE risk of relugolix-CT appears lower than that of traditional combined oral contraceptives. Nonetheless, patient selection is essential, particularly for those with thrombotic risk factors. Continued real-world surveillance is crucial to refining its safety profile in clinical practice.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1210/jendso/bvaf190
- OA Status
- gold
- OpenAlex ID
- https://openalex.org/W4416562462
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4416562462Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1210/jendso/bvaf190Digital Object Identifier
- Title
-
Venous Thromboembolism Risk Associated with Relugolix-Estradiol-Norethisterone Acetate Combination TherapyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-21Full publication date if available
- Authors
-
Marie Didembourg, Charles Chapron, Philippe Descamps, Florence Trémollières, Nathalie Chabbert‐BuffetList of authors in order
- Landing page
-
https://doi.org/10.1210/jendso/bvaf190Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1210/jendso/bvaf190Direct OA link when available
- Cited by
-
0Total citation count in OpenAlex
Full payload
| id | https://openalex.org/W4416562462 |
|---|---|
| doi | https://doi.org/10.1210/jendso/bvaf190 |
| ids.doi | https://doi.org/10.1210/jendso/bvaf190 |
| ids.openalex | https://openalex.org/W4416562462 |
| fwci | 0.0 |
| type | article |
| title | Venous Thromboembolism Risk Associated with Relugolix-Estradiol-Norethisterone Acetate Combination Therapy |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| is_xpac | False |
| apc_list.value | 2822 |
| apc_list.currency | USD |
| apc_list.value_usd | 2822 |
| apc_paid.value | 2822 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2822 |
| language | en |
| locations[0].id | doi:10.1210/jendso/bvaf190 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2735747656 |
| locations[0].source.issn | 2472-1972 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2472-1972 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Journal of the Endocrine Society |
| locations[0].source.host_organization | https://openalex.org/P4310315851 |
| locations[0].source.host_organization_name | Endocrine Society |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315851 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of the Endocrine Society |
| locations[0].landing_page_url | https://doi.org/10.1210/jendso/bvaf190 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5017538074 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9170-0314 |
| authorships[0].author.display_name | Marie Didembourg |
| authorships[0].countries | BE, US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I149768937 |
| authorships[0].affiliations[0].raw_affiliation_string | Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I4210149479 |
| authorships[0].affiliations[1].raw_affiliation_string | QUALIblood sa , Liège , |
| authorships[0].institutions[0].id | https://openalex.org/I149768937 |
| authorships[0].institutions[0].ror | https://ror.org/03d1maw17 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I149768937 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | University of Namur |
| authorships[0].institutions[1].id | https://openalex.org/I4210149479 |
| authorships[0].institutions[1].ror | https://ror.org/04rxwqr66 |
| authorships[0].institutions[1].type | nonprofit |
| authorships[0].institutions[1].lineage | https://openalex.org/I4210149479 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | OneBlood |
| authorships[0].author_position | middle |
| authorships[0].raw_author_name | Marie Didembourg |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Clinical Pharmacology and Toxicology Research Unit, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium, QUALIblood sa , Liège , |
| authorships[1].author.id | https://openalex.org/A5043001702 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2578-3163 |
| authorships[1].author.display_name | Charles Chapron |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I154526488, https://openalex.org/I4210141964 |
| authorships[1].affiliations[0].raw_affiliation_string | Department 3I « Infection, Immunité et inflammation”, Institut Cochin, INSERM U1016 , Paris , |
| authorships[1].affiliations[1].institution_ids | https://openalex.org/I4210097159, https://openalex.org/I4210124464 |
| authorships[1].affiliations[1].raw_affiliation_string | Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Department of Gynaecology Obstetrics and Reproductive Medicine , Paris , |
| authorships[1].affiliations[2].institution_ids | https://openalex.org/I204730241 |
| authorships[1].affiliations[2].raw_affiliation_string | Université de Paris, Faculté de Médecine , Paris , |
| authorships[1].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[1].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[1].institutions[1].id | https://openalex.org/I4210124464 |
| authorships[1].institutions[1].ror | https://ror.org/02v5bgz72 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210124464 |
| authorships[1].institutions[1].country_code | FR |
| authorships[1].institutions[1].display_name | Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale |
| authorships[1].institutions[2].id | https://openalex.org/I154526488 |
| authorships[1].institutions[2].ror | https://ror.org/02vjkv261 |
| authorships[1].institutions[2].type | government |
| authorships[1].institutions[2].lineage | https://openalex.org/I154526488 |
| authorships[1].institutions[2].country_code | FR |
| authorships[1].institutions[2].display_name | Inserm |
| authorships[1].institutions[3].id | https://openalex.org/I4210141964 |
| authorships[1].institutions[3].ror | https://ror.org/051sk4035 |
| authorships[1].institutions[3].type | facility |
| authorships[1].institutions[3].lineage | https://openalex.org/I1294671590, https://openalex.org/I1294671590, https://openalex.org/I154526488, https://openalex.org/I204730241, https://openalex.org/I4210096427, https://openalex.org/I4210141964 |
| authorships[1].institutions[3].country_code | FR |
| authorships[1].institutions[3].display_name | Institut Cochin |
| authorships[1].institutions[4].id | https://openalex.org/I204730241 |
| authorships[1].institutions[4].ror | https://ror.org/05f82e368 |
| authorships[1].institutions[4].type | education |
| authorships[1].institutions[4].lineage | https://openalex.org/I204730241 |
| authorships[1].institutions[4].country_code | FR |
| authorships[1].institutions[4].display_name | Université Paris Cité |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Charles Chapron |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Assistance Publique–Hôpitaux de Paris (AP–HP), Hôpital universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire (CHU) Cochin, Department of Gynaecology Obstetrics and Reproductive Medicine , Paris ,, Department 3I « Infection, Immunité et inflammation”, Institut Cochin, INSERM U1016 , Paris ,, Université de Paris, Faculté de Médecine , Paris , |
| authorships[2].author.id | https://openalex.org/A5011433469 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-4280-3237 |
| authorships[2].author.display_name | Philippe Descamps |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I49451733 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Obstetrics and Gynecology, University Hospital of Angers, Angers, France |
| authorships[2].institutions[0].id | https://openalex.org/I49451733 |
| authorships[2].institutions[0].ror | https://ror.org/04yrqp957 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I49451733 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Université d'Angers |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Philippe Descamps |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Obstetrics and Gynecology, University Hospital of Angers, Angers, France |
| authorships[3].author.id | https://openalex.org/A5110146815 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Florence Trémollières |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210153496 |
| authorships[3].affiliations[0].raw_affiliation_string | Centre de Ménopause, Hôpital Paule-de-Viguier, CHU Toulouse , Toulouse , |
| authorships[3].institutions[0].id | https://openalex.org/I4210153496 |
| authorships[3].institutions[0].ror | https://ror.org/057vt8c33 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I3019448017, https://openalex.org/I4210153496 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Hôpital Paule de Viguier |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Florence Tremollières |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Centre de Ménopause, Hôpital Paule-de-Viguier, CHU Toulouse , Toulouse , |
| authorships[4].author.id | https://openalex.org/A5050225719 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-6525-4154 |
| authorships[4].author.display_name | Nathalie Chabbert‐Buffet |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210166768 |
| authorships[4].affiliations[0].raw_affiliation_string | Service de Gynécologie, Obstétrique et Médecine de la Reproduction, Hôpital Tenon (AP-HP), Sorbonne-Université , Paris , |
| authorships[4].institutions[0].id | https://openalex.org/I4210166768 |
| authorships[4].institutions[0].ror | https://ror.org/05h5v3c50 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210166768 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Hôpital Tenon |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Nathalie Chabbert-Buffet |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Service de Gynécologie, Obstétrique et Médecine de la Reproduction, Hôpital Tenon (AP-HP), Sorbonne-Université , Paris , |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1210/jendso/bvaf190 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-25T00:00:00 |
| display_name | Venous Thromboembolism Risk Associated with Relugolix-Estradiol-Norethisterone Acetate Combination Therapy |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-28T17:25:17.164967 |
| primary_topic | |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1210/jendso/bvaf190 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2735747656 |
| best_oa_location.source.issn | 2472-1972 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2472-1972 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Journal of the Endocrine Society |
| best_oa_location.source.host_organization | https://openalex.org/P4310315851 |
| best_oa_location.source.host_organization_name | Endocrine Society |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315851 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Journal of the Endocrine Society |
| best_oa_location.landing_page_url | https://doi.org/10.1210/jendso/bvaf190 |
| primary_location.id | doi:10.1210/jendso/bvaf190 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2735747656 |
| primary_location.source.issn | 2472-1972 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2472-1972 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Journal of the Endocrine Society |
| primary_location.source.host_organization | https://openalex.org/P4310315851 |
| primary_location.source.host_organization_name | Endocrine Society |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315851 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of the Endocrine Society |
| primary_location.landing_page_url | https://doi.org/10.1210/jendso/bvaf190 |
| publication_date | 2025-11-21 |
| publication_year | 2025 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 59, 130 |
| abstract_inverted_index.a | 124, 137 |
| abstract_inverted_index.1, | 65, 69 |
| abstract_inverted_index.2, | 67 |
| abstract_inverted_index.E2 | 103 |
| abstract_inverted_index.an | 3 |
| abstract_inverted_index.in | 12, 99, 127, 181 |
| abstract_inverted_index.is | 10, 162, 174 |
| abstract_inverted_index.of | 47, 61, 148, 154 |
| abstract_inverted_index.on | 50, 83 |
| abstract_inverted_index.to | 96, 176 |
| abstract_inverted_index.2), | 71 |
| abstract_inverted_index.The | 145 |
| abstract_inverted_index.VTE | 87, 128, 146 |
| abstract_inverted_index.and | 16, 35, 55, 76, 86, 104, 118 |
| abstract_inverted_index.for | 165 |
| abstract_inverted_index.its | 29, 178 |
| abstract_inverted_index.not | 122 |
| abstract_inverted_index.the | 22, 44 |
| abstract_inverted_index.was | 80 |
| abstract_inverted_index.(E2) | 34 |
| abstract_inverted_index.NETA | 105 |
| abstract_inverted_index.This | 40 |
| abstract_inverted_index.data | 79 |
| abstract_inverted_index.have | 121, 136 |
| abstract_inverted_index.oral | 4, 32, 157 |
| abstract_inverted_index.risk | 26, 46, 140, 147, 169 |
| abstract_inverted_index.than | 141, 152 |
| abstract_inverted_index.that | 133, 153 |
| abstract_inverted_index.with | 28, 31, 167 |
| abstract_inverted_index.(EMA, | 74 |
| abstract_inverted_index.(VTE) | 25 |
| abstract_inverted_index.FDA), | 75 |
| abstract_inverted_index.While | 102 |
| abstract_inverted_index.about | 110 |
| abstract_inverted_index.based | 49 |
| abstract_inverted_index.data, | 52 |
| abstract_inverted_index.lower | 138, 151 |
| abstract_inverted_index.minor | 97 |
| abstract_inverted_index.risk. | 88, 129 |
| abstract_inverted_index.shown | 123 |
| abstract_inverted_index.their | 111 |
| abstract_inverted_index.those | 166 |
| abstract_inverted_index.(GnRH) | 7 |
| abstract_inverted_index.SPIRIT | 68, 70 |
| abstract_inverted_index.expert | 41 |
| abstract_inverted_index.myomas | 15 |
| abstract_inverted_index.review | 60 |
| abstract_inverted_index.safety | 78, 179 |
| abstract_inverted_index.trials | 63, 117 |
| abstract_inverted_index.venous | 23 |
| abstract_inverted_index.(NETA). | 38 |
| abstract_inverted_index.LIBERTY | 66 |
| abstract_inverted_index.Methods | 58 |
| abstract_inverted_index.Results | 89 |
| abstract_inverted_index.acetate | 37 |
| abstract_inverted_index.appears | 150 |
| abstract_inverted_index.crucial | 175 |
| abstract_inverted_index.effects | 85 |
| abstract_inverted_index.hormone | 6 |
| abstract_inverted_index.leading | 95 |
| abstract_inverted_index.levels, | 94 |
| abstract_inverted_index.opinion | 42 |
| abstract_inverted_index.patient | 160 |
| abstract_inverted_index.persist | 20 |
| abstract_inverted_index.pivotal | 62 |
| abstract_inverted_index.profile | 180 |
| abstract_inverted_index.reduces | 92 |
| abstract_inverted_index.remain. | 114 |
| abstract_inverted_index.reports | 73 |
| abstract_inverted_index.trials, | 54 |
| abstract_inverted_index.uterine | 14 |
| abstract_inverted_index.(LIBERTY | 64 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 18, 115 |
| abstract_inverted_index.clinical | 53, 116, 182 |
| abstract_inverted_index.combined | 156 |
| abstract_inverted_index.concerns | 19, 109 |
| abstract_inverted_index.effects, | 108 |
| abstract_inverted_index.estrogen | 93 |
| abstract_inverted_index.factors. | 101, 170 |
| abstract_inverted_index.focusing | 82 |
| abstract_inverted_index.increase | 126 |
| abstract_inverted_index.mitigate | 106 |
| abstract_inverted_index.receptor | 8 |
| abstract_inverted_index.refining | 177 |
| abstract_inverted_index.regimens | 135 |
| abstract_inverted_index.suggests | 132 |
| abstract_inverted_index.treating | 13 |
| abstract_inverted_index.Continued | 171 |
| abstract_inverted_index.Objective | 39 |
| abstract_inverted_index.Relugolix | 90 |
| abstract_inverted_index.decreases | 98 |
| abstract_inverted_index.effective | 11 |
| abstract_inverted_index.estradiol | 33 |
| abstract_inverted_index.evaluates | 43 |
| abstract_inverted_index.potential | 113 |
| abstract_inverted_index.practice. | 183 |
| abstract_inverted_index.regarding | 21 |
| abstract_inverted_index.selection | 161 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Relugolix, | 2 |
| abstract_inverted_index.associated | 27 |
| abstract_inverted_index.conducted, | 81 |
| abstract_inverted_index.essential, | 163 |
| abstract_inverted_index.hemostatic | 84 |
| abstract_inverted_index.real-world | 77, 172 |
| abstract_inverted_index.regulatory | 56, 72 |
| abstract_inverted_index.therapies. | 143 |
| abstract_inverted_index.thrombotic | 45, 139, 168 |
| abstract_inverted_index.Conclusions | 144 |
| abstract_inverted_index.antagonist, | 9 |
| abstract_inverted_index.coagulation | 100 |
| abstract_inverted_index.combination | 30 |
| abstract_inverted_index.monotherapy | 91 |
| abstract_inverted_index.significant | 125 |
| abstract_inverted_index.traditional | 155 |
| abstract_inverted_index.Nonetheless, | 159 |
| abstract_inverted_index.assessments. | 57 |
| abstract_inverted_index.particularly | 164 |
| abstract_inverted_index.relugolix-CT | 48, 149 |
| abstract_inverted_index.surveillance | 120, 173 |
| abstract_inverted_index.meta-analysis | 131 |
| abstract_inverted_index.prothrombotic | 112 |
| abstract_inverted_index.endometriosis. | 17 |
| abstract_inverted_index.hypoestrogenic | 107 |
| abstract_inverted_index.norethisterone | 36 |
| abstract_inverted_index.post-marketing | 119 |
| abstract_inverted_index.contraceptives. | 158 |
| abstract_inverted_index.estradiol-based | 134 |
| abstract_inverted_index.pharmacological | 51 |
| abstract_inverted_index.thromboembolism | 24 |
| abstract_inverted_index.ethinylestradiol-based | 142 |
| abstract_inverted_index.gonadotropin-releasing | 5 |
| cited_by_percentile_year | |
| countries_distinct_count | 3 |
| institutions_distinct_count | 5 |
| citation_normalized_percentile |